Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 30, 2025 16:05 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
December 04, 2024 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza

SAN DIEGO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
November 21, 2024 08:30 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Announces $105 Million Private Placement

SAN DIEGO, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
November 19, 2024 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference

SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
November 07, 2024 16:15 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate...
October 31, 2024 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
October 16, 2024 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024

SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
October 04, 2024 16:30 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
September 25, 2024 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference

SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...
September 23, 2024 08:00 ET | Source: Cidara Therapeutics, Inc.

Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza

SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right